Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment (Q36424963)

14 August 2017

1 reference

title

Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment (English)

1 reference

14 August 2017

anti-retroviral agent

0 references

0 references

0 references

Elizabeth L Corbett

1

0 references

Gavin J Churchyard

series ordinal

3

object named as

Gavin J Churchyard

1 reference

14 August 2017

4

Kevin M De Cock

1 reference

14 August 2017

Barbara Marston

2

1 reference

PubMed ID

16546541

14 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

14 August 2017

1 reference

14 August 2017

367

1 reference

14 August 2017

9514

1 reference

14 August 2017

926-937

1 reference

Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

The growing burden of tuberculosis: global trends and interactions with the HIV epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Chronic cough in primary health care attendees, Harare, Zimbabwe: diagnosis and impact of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

The mortality and pathology of HIV infection in a west African city.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

A clinical and pathological comparison of the WHO and CDC case definitions for AIDS in Kinshasa, Zaïre: is passive surveillance valid?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Screening pulmonary tuberculosis suspects in Malawi: testing different strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Prevalence of tuberculosis in TB suspects with short duration of cough

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Fatal Mycobacterium tuberculosis bloodstream infections in febrile hospitalized adults in Dar es Salaam, Tanzania

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Chronic diarrhoea among HIV-infected adult patients in Nairobi, Kenya.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Tuberculosis control and molecular epidemiology in a South African gold-mining community

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Cohort study of HIV-positive and HIV-negative tuberculosis, Nairobi, Kenya: comparison of bacteriological results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

New measurable indicator for tuberculosis case detection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

The International Union Against Tuberculosis and Lung Disease model National Tuberculosis Programmes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Tuberculosis preventive therapy in HIV-infected individuals. A joint statement of the International Union Against Tuberculosis and Lung Disease (IUATLD) and the Global Programme on AIDS and the Tuberculosis Programme of the World Health Organization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Molecular and conventional epidemiology of Mycobacterium tuberculosis in Botswana: a population-based prospective study of 301 pulmonary tuberculosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Trends in tuberculosis and the influence of HIV infection in northern Malawi, 1988-2001.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Impact of the HIV epidemic on trends in tuberculosis in Abidjan, Côte d'Ivoire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Stable incidence rates of tuberculosis (TB) among human immunodeficiency virus (HIV)-negative South African gold miners during a decade of epidemic HIV-associated TB.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

The evolving epidemiology of HIV infection and tuberculosis in northern Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Tuberculosis and the HIV epidemic: increasing annual risk of tuberculous infection in Kenya, 1986-1996

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Trends in tuberculosis and the influence of HIV infection in northern Malawi, 1988-2001.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Autopsy-proven causes of death in HIV-infected patients treated for tuberculosis in Abidjan, Côte d'Ivoire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Voluntary counselling, HIV testing and adjunctive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Changing Clinical Presentation and Survival in HIV-Associated Tuberculosis After Highly Active Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Tuberculosis epidemics driven by HIV: is prevention better than cure?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Integrating tuberculosis and HIV care in the primary care setting in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Shadow on the continent: public health and HIV/AIDS in Africa in the 21st century

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Radiologic manifestations of pulmonary tuberculosis in HIV-1 and HIV-2-infected patients in Abidjan, Côte d'Ivoire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Chest radiographic findings in patients with tuberculosis with recent or remote infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Value of chest radiography in a tuberculosis prevention programme for HIV-infected people, Botswana

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Tuberculosis in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Antituberculosis drug resistance and anonymous HIV surveillance in tuberculosis patients in Botswana, 2002.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Clinical management of tuberculosis in the context of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

The sound of one hand clapping: tuberculosis and antiretroviral therapy in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Monitoring the response to antiretroviral therapy in resource-poor settings: the Malawi model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Scaling up access to antiretroviral treatment in southern Africa: who will do the job?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Human resources for health: overcoming the crisis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

Resources required for global tuberculosis control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968383-9

7 January 2021

10.1016/S0140-6736(06)68383-9

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16546541